JPWO2021195530A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021195530A5 JPWO2021195530A5 JP2022558017A JP2022558017A JPWO2021195530A5 JP WO2021195530 A5 JPWO2021195530 A5 JP WO2021195530A5 JP 2022558017 A JP2022558017 A JP 2022558017A JP 2022558017 A JP2022558017 A JP 2022558017A JP WO2021195530 A5 JPWO2021195530 A5 JP WO2021195530A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antagonist
- composition according
- subject
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 33
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims 29
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims 29
- 239000005557 antagonist Substances 0.000 claims 28
- 206010012438 Dermatitis atopic Diseases 0.000 claims 14
- 201000008937 atopic dermatitis Diseases 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 208000003251 Pruritus Diseases 0.000 claims 4
- 229940071643 prefilled syringe Drugs 0.000 claims 4
- 230000000699 topical effect Effects 0.000 claims 4
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 2
- 206010016946 Food allergy Diseases 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 229940090047 auto-injector Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 235000020932 food allergy Nutrition 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010027654 Allergic conditions Diseases 0.000 claims 1
- 206010003645 Atopy Diseases 0.000 claims 1
- 102100023698 C-C motif chemokine 17 Human genes 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 1
- 101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 claims 1
- 208000000592 Nasal Polyps Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 239000000090 biomarker Substances 0.000 claims 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 229950003468 dupilumab Drugs 0.000 claims 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 238000002483 medication Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063001224P | 2020-03-27 | 2020-03-27 | |
| US63/001,224 | 2020-03-27 | ||
| EP21315010 | 2021-01-28 | ||
| EP21315010.5 | 2021-01-28 | ||
| PCT/US2021/024419 WO2021195530A1 (en) | 2020-03-27 | 2021-03-26 | Methods for treating atopic dermatitis by administering an il-4r antagonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023520676A JP2023520676A (ja) | 2023-05-18 |
| JPWO2021195530A5 true JPWO2021195530A5 (ko) | 2024-04-03 |
Family
ID=75498103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022558017A Pending JP2023520676A (ja) | 2020-03-27 | 2021-03-26 | Ｉｌ－４ｒアンタゴニストを投与することによりアトピー性皮膚炎を処置するための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230102151A1 (ko) |
| EP (1) | EP4126951A1 (ko) |
| JP (1) | JP2023520676A (ko) |
| KR (1) | KR20220158821A (ko) |
| CN (1) | CN115427450A (ko) |
| AU (1) | AU2021244266A1 (ko) |
| BR (1) | BR112022015363A2 (ko) |
| CA (1) | CA3173173A1 (ko) |
| IL (1) | IL296214A (ko) |
| MX (1) | MX2022011730A (ko) |
| WO (1) | WO2021195530A1 (ko) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA46098A (fr) | 2016-09-01 | 2019-07-10 | Regeneron Pharma | Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r |
| WO2020191346A1 (en) | 2019-03-21 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
| CA3147113A1 (en) | 2019-08-05 | 2021-02-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| JP2024532263A (ja) | 2021-08-23 | 2024-09-05 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｉｌ－４ｒアンタゴニストを投与することによってアトピー性皮膚炎を治療する方法 |
| CN118355034A (zh) * | 2021-12-30 | 2024-07-16 | 瑞泽恩制药公司 | 施用il-4/il-13拮抗剂以减弱特应性进程的方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2292665B1 (en) | 2000-05-26 | 2015-07-08 | Immunex Corporation | Use of interleukin-4 antibodies and compositions thereof |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| ATE548388T1 (de) | 2003-11-07 | 2012-03-15 | Immunex Corp | An den interleukin-4-rezeptor bindende antikörper |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| MX2009003393A (es) | 2006-10-02 | 2009-05-11 | Regeneron Pharma | Anticuerpos humanos de alta afinidad para el receptor de il-4 humano. |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| PL2624865T3 (pl) | 2010-10-06 | 2018-11-30 | Regeneron Pharmaceuticals, Inc. | Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny-4 (IL-4R) |
| WO2014039461A1 (en) | 2012-09-07 | 2014-03-13 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| JP2019505554A (ja) * | 2016-02-19 | 2019-02-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｉｌ−４ｒアンタゴニストを投与することによるワクチンの有効性を増強する方法 |
| CN113372446A (zh) | 2016-06-08 | 2021-09-10 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
| WO2018057776A1 (en) | 2016-09-22 | 2018-03-29 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an il-4r inhibitor |
| EP3878868A4 (en) | 2018-11-09 | 2022-07-27 | Ajou University Industry-Academic Cooperation Foundation | HUMAN ANTIBODY WITH HIGH AFFINITY TO AND USE OF HUMAN IL-4 RECEPTOR ALPHA |
-
2021
- 2021-03-26 JP JP2022558017A patent/JP2023520676A/ja active Pending
- 2021-03-26 MX MX2022011730A patent/MX2022011730A/es unknown
- 2021-03-26 IL IL296214A patent/IL296214A/en unknown
- 2021-03-26 US US17/907,070 patent/US20230102151A1/en active Pending
- 2021-03-26 EP EP21718786.3A patent/EP4126951A1/en active Pending
- 2021-03-26 KR KR1020227037517A patent/KR20220158821A/ko active Search and Examination
- 2021-03-26 BR BR112022015363A patent/BR112022015363A2/pt unknown
- 2021-03-26 CN CN202180024611.8A patent/CN115427450A/zh active Pending
- 2021-03-26 WO PCT/US2021/024419 patent/WO2021195530A1/en active Application Filing
- 2021-03-26 CA CA3173173A patent/CA3173173A1/en active Pending
- 2021-03-26 AU AU2021244266A patent/AU2021244266A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210130451A1 (en) | Treatment for rheumatoid arthritis | |
| EP4011915B1 (en) | Methods for treating or preventing asthma by administering an il-4r antagonist | |
| JP6554155B2 (ja) | Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法 | |
| RU2759630C2 (ru) | Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r | |
| JP2019529560A5 (ko) | ||
| EP3487881B1 (en) | Methods of treating new-onset plaque type psoriasis using il-17 antagonists | |
| JP2021502349A5 (ko) | ||
| JP2023520676A (ja) | Ｉｌ－４ｒアンタゴニストを投与することによりアトピー性皮膚炎を処置するための方法 | |
| JPWO2021026205A5 (ko) | ||
| He et al. | New options for uveitis treatment | |
| JP2024016237A5 (ko) | ||
| JPWO2019222055A5 (ko) | ||
| JP2021147383A (ja) | アトピー性皮膚炎及び関連障害を処置するための方法 | |
| JPWO2021195530A5 (ko) | ||
| WO2022258814A1 (en) | Methods for treating atopic dermatitis and related disorders | |
| RU2024107446A (ru) | Способы лечения атопического дерматита посредством введения антагониста il-4r | |
| RU2022105374A (ru) | Способы лечения атопического дерматита посредством введения антагониста il-4r | |
| RU2024105814A (ru) | Лечение атопического дерматита | |
| RU2024121393A (ru) | Способы ослабления атопического марша посредством введения антагониста il-4/il-13 | |
| RU2020140639A (ru) | Способы лечения атопического дерматита посредством введения ингибитора ил-4r | |
| NZ769607B2 (en) | Methods for treating atopic dermatitis by administering an il-4r inhibitor | |
| WO2021191220A1 (en) | Methods for treating atopic dermatitis and related disorders | |
| NZ769607A (en) | Methods for treating atopic dermatitis by administering an il-4r inhibitor | |
| JP2019178153A (ja) | Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法 |